Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model
2025; Elsevier BV; Volume: 112; Linguagem: Inglês
10.1016/j.ebiom.2024.105543
ISSN2352-3964
AutoresCarole Fournier, Marion Mercey-Ressejac, Valentin Dérangère, Amal Al Kadi, David Rageot, C. Charrat, Alexis Leroy, Julien Vollaire, Véronique Josserand, Marie Escudé, Séverine Escaich, François Ghiringhelli, Thomas Decaens, Fabrice Navarro, Evelyne Jouvin‐Marche, Patrice N. Marche,
Tópico(s)Cancer Immunotherapy and Biomarkers
Referência(s)